Three major North American surveillance programs have tracked antimicrobial resistance patterns among isolates of Streptococcus pneumoniae and other common respiratory tract pathogens. The Canadian Bacterial Surveillance Network shows the progressive increase in resistance among pneumococcal S. pneumoniae to penicillin, trimethoprim-sulfamethoxazole, macrolides, and fluoroquinolones. The data from the Tracking Resistance in the United States Today study also show a steady rise in pneumococcal resistance among common antibiotics as well as an increase in multidrug-resistant S. pneumoniae. The US component of the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study has detected increasing resistance to many antimicrobial agents among common respiratory isolates, with marked geographic variations in resistance patterns. The patterns of resistance detected by these major surveillance programs are a warning signal regarding the continued emergence of resistance among community-acquired respiratory tract pathogens.
of bacterial CAP are caused by S. pneumoniae, although "atypical pathogens" (e.g., Mycoplasma pneumoniae, Legionella species, and Chlamydia pneumoniae) have been implicated in up to 40% of cases of CAP requiring hospitalization [4] . These atypical agents often occur as copathogens in cases of "mixed-infection" CAP, which is associated with a mortality rate as high as 25% [4] .
A minority of episodes of acute sinusitis are caused by bacteria; however, when acute bacterial sinusitis develops, a condition that affects 20 million adults in the United States annually, antimicrobial therapy is indicated [5] . (For a detailed discussion of sinusitis, see the study by Sande and Gwaltney [6] in this supplement issue of Clinical Infectious Diseases.) The majority of cases of acute bacterial sinusitis-the fifth most common diagnosis for which antimicrobial agents are prescribed today-are caused by S. pneumoniae and H. influenzae [7, 8] .
Although the cause of acute exacerbations of chronic bronchitis is often nonbacterial, bacteria, most commonly S. pneumoniae, M. catarrhalis, or H. influenzae, cause this condition as a complication of chronic obstructive lung disease. Acute exacerbation of chronic bronchitis accounts for 114 million office visits to primary care physicians and 500,000 hospital admissions in the United States annually [9] . It is not surprising that the total direct and indirect costs associated with these important RTIs are substantial and are estimated to approach $23 billion annually for CAP, 1$2 billion for acute exacerbation of chronic bronchitis, and ∼$6 billion for acute bacterial sinusitis [3, 9] . The causative pathogens responsible for the majority of these infections are developing resistance to our current antimicrobial armamentarium; thus, an urgent need exists for new agents as well as for thorough surveillance programs designed to track resistance patterns among respiratory pathogens, both in the United States and abroad, and studies to assess the impact of degrees of resistance on the efficacy of antimicrobial therapy.
Several major US and Canadian monitoring programs have recently been initiated; their findings have revealed disturbing patterns of antimicrobial resistance among respiratory tract pathogens [10] [11] [12] [13] [14] [15] . There is widespread variability in the resistance trends identified, depending on factors such as the respiratory isolate evaluated, the class of the antimicrobial agent tested, the geographic region where the specimen was collected, and various patient characteristics, such as age and site of infection. Here I provide an overview of the key findings from these major North American surveillance initiatives.
CANADIAN BACTERIAL SURVEILLANCE NETWORK
The Canadian Bacterial Surveillance Network, a major Canadian surveillance initiative, started in 1988. In this initiative, 15,677 isolates of S. pneumoniae were collected at 181 laboratories throughout Canada and tested according to the National Committee for Clinical Laboratory Standards protocols.
As shown in figure 1 [10] , there has been an increase in resistance among S. pneumoniae to penicillin, trimethoprimsulfamethoxazole, macrolides, and fluoroquinolones [10] . The incidence of penicillin-resistant S. pneumoniae increased from 0 in 1988 to 7% in 2001, and the incidence of trimethoprimsulfamethoxazole-resistant S. pneumoniae increased from 3.7% to 12.0% over this same period. Of greater concern is the increase in the frequency of S. pneumoniae that are macrolideresistant. The Canadian data indicate that the number of erythromycin-resistant S. pneumoniae isolates increased from 1.2% to 13.1% and the number of clindamycin-resistant organisms increased from 1.2% to 5.8% over the 13-year tracking effort [10] .
THE TRUST STUDY
The Tracking Resistance in the United States Today (TRUST) study, started in 1996, is currently the longest-running surveillance program conducted in the United States to track resistance among respiratory tract pathogens [11] [12] [13] [14] [15] Increase in pneumococcal resistance to penicillin and other antibiotics. The TRUST data have demonstrated an increase in high-level penicillin resistance (MIC of у2 mg/mL) among respiratory strains of S. pneumoniae, beginning as early as the mid-1990s (figure 2) [11] [12] [13] [14] [15] [16] [17] . During the 1994-1995 RTI season, the frequency of overall reduced susceptibility to penicillin (MIC of 10.1 mg/mL) was 23.6% and that of high-level resistance was 9.5%. A steady increase in the frequency of highlevel penicillin resistance among pneumococci was noted during the 1997-1998 through 2000-2001 RTI seasons. During these periods, the frequency of overall reduced susceptibility to penicillin ranged from 33.1% to 35.6% and of high-level resistance ranged from 13% to 16.9% [18] .
As shown in figure 3 [12, 15, 19] , roughly 18% of pneumococci showed intermediate penicillin resistance (MIC of 0.1-1.0 mg/mL) during the 3 annual tracking seasons that spanned the RTI seasons from 1998 to 2001 [11, 12, 15] . However, there was a trend indicating an overall increase in penicillin-resistant S. pneumoniae isolates over this period, from 33.1% in the 1999 season to 35.6% in 2001. This increase may be best accounted for by the increase in isolates with high-level penicillin resistance (MIC of у2.0 mg/mL), from 14.7% to 16.9%, over the same tracking period [11, 12, 15, 19] .
There has also been an increase in resistance among S. pneumoniae organisms to other widely used antimicrobial agents, including azithromycin and ceftriaxone. Overall resistance to azithromycin was found to be 23.0% during the 1998-1999 RTI season, compared with 28.0% during the 2000-2001 season. Overall resistance to ceftriaxone also rose from 15.5% to a peak of 17.1% over this same period. Although most pneumococci still remained susceptible to levofloxacin, the TRUST data suggest that the incidence of resistance to this fluoroquinolone is slowly increasing (figure 3) [12, 15, 19] .
Increase in multidrug-resistant S. pneumoniae. Another growing concern is the increase in the frequency of multidrugresistant S. pneumoniae (resistant to у3 antimicrobial classes, most commonly penicillin, trimethoprim-sulfamethoxazole, and macrolides). The TRUST data show that only 6.2% of S. pneumoniae isolates were multidrug-resistant during the 1998 RTI season, whereas 13.5% were multidrug-resistant in the 2001 season (figure 4) [11, 12, 20, 21] (data on file, Ortho-McNeil Pharmaceuticals).
An evaluation of 6362 S. pneumoniae isolates collected during the 2000-2001 RTI season showed that 98.0% of the 1077 isolates with high-level penicillin resistance also were resistant to cefuroxime (table 1) [11] . The respective resistance rates for trimethoprim-sulfamethoxazole and azithromycin were 88.1% and 80.2%. In addition, 17.1% of penicillin-resistant pneumococci were ceftriaxone-resistant, and 1.4% were levofloxacin-resistant. Conversely, none of the 4096 strains of S. pneumoniae that were penicillin-susceptible (MIC of р0.06 mg/mL) were resistant to ceftriaxone or cefuroxime; 5.8% and 6.0% were resistant to azith- romycin and trimethoprim-sulfamethoxazole, respectively, and 0.5% were resistant to levofloxacin [11] .
The most common multidrug-resistant phenotype was resistance to penicillin, azithromycin, and trimethoprim-sulfamethoxazole, which constituted 75.2% of multidrug-resistant isolates in 1997-1998 and 92.1% of isolates in 2000-2001 [11] . The authors concluded that double-drug and multidrug resistance to commonly prescribed antimicrobial agents continues to emerge in S. pneumoniae.
PROTEKT US: A MAJOR SURVEILLANCE STUDY
In 1999, a longitudinal global surveillance study-the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) study-was initiated to assess the prevalence of antimicrobial resistance among respiratory tract pathogens in 25 countries [22] . The US-focused component of this surveillance program (PROTEKT US) was initiated in 2000 and collected respiratory pathogens from 206 sites in 41 states. There were 4 primary objectives of this initiative: to obtain MIC end points that would allow investigators to interpret data according to various susceptibility break-point criteria, to chart the prevalence of important resistance phenotypes and genotypes, to assess the in vitro activity of the ketolide telithromycin against a variety of resistant respiratory strains isolated in different laboratories, and to collect demographic data that would permit analyses of resistance by infection type and patient characteristics over time.
The antibiotics used to test the resistance patterns of the respiratory isolates collected in the PROTEKT US program are penicillin, amoxicillin-clavulanate, tetracycline, trimethoprimsulfamethoxazole, cefuroxime, clindamycin, erythromycin, clarithromycin, azithromycin, levofloxacin, gatifloxacin, linezolid, and telithromycin. During the initial 2000-2001 respiratory tracking season, a total of 16,727 respiratory isolates were collected at the 206 PROTEKT US sites [23] . In 2001-2002 RTI season, ∼17,816 respiratory isolates were collected at the 242 PROTEKT US sites [24] . The majority (∼60%) of the 2000- 2001 isolates were strains of S. pneumoniae, whereas the remainder comprised S. pyogenes (∼23%) and H. influenzae (∼16%) [23, 25, 26] .
Increasing resistance to antimicrobial agents. On the basis of the PROTEKT US data for the 2000-2001 RTI season, highlevel penicillin resistance was found in 2654 (26.3%) and erythromycin resistance was noted in 3133 (31%) of the 10,103 S. pneumoniae isolates (table 2) . Although the prevalence of macrolide resistance in PROTEKT US is significantly higher than that observed in the Canadian study, it approximates relatively closely the 28% resistance rate noted in the 2000-2001 season in the TRUST data (figure 3) [10, 26] . Notably among penicillinresistant S. pneumoniae, macrolide resistance occurred in 78% of isolates, again similar to the co-resistance rates noted in the TRUST data [26] . Overall, the incidence of levofloxacin resistance was relatively low, 0.8% [27] .
The findings of PROTEKT US also show the emergence of resistance among other common respiratory pathogens, such as H. influenzae and S. pyogenes. Of the 2706 H. influenzae isolates tested during the 2000-2001 tracking period, 765 (28.3%) were found to be b-lactamase-positive and 0.9% b-lactamase-negative, ampicillin-resistant. In contrast, all of the S. pyogenes isolates were susceptible to penicillin and 3701 (94.5%) of the 3918 S. pyogenes isolates tested were still susceptible to erythromycin, but 213 (5.4%) were erythromycin-resistant [26] .
Geographic variations in S. pneumoniae resistance. Data from PROTEKT US show marked variability in the prevalence of resistance among strains of S. pneumoniae in different regions of the United States (figure 5). Penicillin resistance in the 10,103 strains of S. pneumoniae collected in 41 states was most pronounced in the southeastern and south-central regions of the United States (36.4% and 32.5%, respectively) and lowest in the northwestern region (17.3%). Macrolide resistance was also most prevalent in the southeastern and south-central states (40.2% and 38.6%, respectively) and lowest in the northwestern region (23.2%). Although fluoroquinolone resistance remained quite low in all regions studied, there was a slightly higher incidence of pneumococcal resistance to this class of antibiotics in the northeastern and northwestern states (1.3% and 0.9%, respectively) than in other parts of the country [27] .
Although artifacts may be introduced by sampling, this variability was also evident when data for patterns of penicillin, macrolide, and fluoroquinolone resistance from specific states and cities were analyzed. At the state level, penicillin resistance was most common in Oklahoma and Utah but least common in Washington, DC, and Minnesota. Erythromycin resistance was most common in Oklahoma and Arkansas and least common in Massachusetts and Minnesota. Fluoroquinolone resistance was highest in Massachusetts and Colorado but was not reported in 17 states across the country (table 3) (data on file, Aventis Pharmaceuticals).
An analysis of local pneumococcal resistance to penicillin or macrolides suggests that resistance rates can be notable in specific sites. Analysis of the prevalence of resistance at the local level showed that penicillin resistance occurred in 58.8% of the S. pneumoniae isolates tested in Waycross, Georgia, whereas erythromycin resistance, at 68.7%, was very prevalent among pneumococci isolates in Cedar Rapids, Iowa (data on file, Aventis Pharmaceuticals). In another study, fluoroquinolone resis- tance among S. pneumoniae isolates was prevalent in the Boston area (21.8%) [28] . Overall, the data for the 10,103 strains of S. pneumoniae collected from the 154 cities or metropolitan areas included in the PROTEKT US surveillance system illustrated the breadth of antimicrobial resistance; penicillin-resistant isolates were detected in 150 (97.4%) of the cities or areas, erythromycinresistant isolates were detected in 153 (99.4%), and fluoroquinolone-resistant isolates were identified in 46 (29.9%).
S. pneumoniae isolates highly susceptible to telithromycin. As previously mentioned, one objective of the PROTEKT US study was to evaluate the susceptibility of the 10,103 strains of S. pneumoniae, collected during the 2000-2001 RTI season, to telithromycin in comparison with other agents. The results of these comparisons are presented in table 4 .
S. pneumoniae isolates were more susceptible to telithromycin than to the b-lactam agents tested. As shown in table 4, 99.7% of pneumococci were susceptible to telithromycin, whereas 91.1% were susceptible to amoxicillin-clavulanate, 68.7% were susceptible to cefuroxime, and 61.2% were susceptible to penicillin. As can be seen, similar patterns were detected for most macrolides. Although 90.9% of S. pneumoniae remained susceptible to clindamycin, only ∼69% of organisms remained susceptible to erythromycin, clarithromycin, or azithromycin. Overall, the susceptibility of S. pneumoniae to telithromycin was 99.7%, comparable to that of the fluoroquinolones and linezolid [26] .
Of particular note is that virtually all of the 84 fluoroquinolone-resistant strains of S. pneumoniae collected during the 2000-2001 RTI season were susceptible to telithromycin, whereas only 85% of organisms were susceptible to clindamycin or amoxicillin-clavulanate. About 73% were susceptible to tetracycline, and only about half were susceptible to azithromycin, clarithromycin, cefuroxime, or erythromycin (figure 6) (data on file, Aventis Pharmaceuticals).
Clinical implications of increasing antimicrobial resistance. Although in vitro data do not necessarily correlate with clinical responses to antimicrobial therapy, several recent reports suggest that in vitro resistance may predict decreased clinical efficacy of an agent. For instance, several cases of "breakthrough" bacteremia have recently been reported in patients with CAP due to macrolide-resistant strains of S. pneumoniae [29, 30] . In one report of 41 patients hospitalized with pneumococcal bacteremia between July 1998 and June 1999, 4 patients had breakthrough bacteremia while receiving azithromycin or clarithromycin [29] . All of these patients had infections caused by S. pneumoniae that demonstrated low-level macrolide resistance. Likewise, a recent case-control study of patients with bacteremic pneumococcal infection seen at 4 hospitals in the United States and abroad revealed that patients bacteremic with erythromycin-resistant isolates of S. pneumoniae were more likely to have been receiving macrolide therapy at the time blood was obtained for culture than were those patients bacteremic with macrolide-susceptible S. pneumoniae isolates [31] . The authors suggest this implies a significant risk of macrolide failure in patients infected with macrolide-resistant S. pneumoniae; however, this conclusion is in fact an indirect inference from the data. Nevertheless, because of the possible increased risk of clinical failure of macrolides when treating infection caused by macrolide-resistant isolates, some investigators now recommend that macrolides not be used for empirical therapy for patients with serious presumed pneumococcal infections [29] .
Increased fluoroquinolone resistance. A disturbing early trend identified by the surveillance programs is the emergence of resistance to the fluoroquinolones among S. pneumoniae. The Canadian, TRUST, and PROTEKT US surveillance data show fluoroquinolone resistance increasing, with rates ranging from 0.8% to 1.8% [11, 32] . The Canadian data show that resistance is emerging throughout the entire fluoroquinolone class. Among Canadian isolates, rates of resistance to ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin were 1.8%, 0.7%, 0.6%, and 0.3%, respectively. The authors concluded that ciprofloxacin-resistant, levofloxacin-susceptible S. pneumoniae have first-step mutations reducing fluoroquinolone susceptibility and are at risk of developing resistance to the other more potent members of the fluoroquinolone class of antimicrobials [32] .
Fluoroquinolone resistance is of special concern in elderly patients, because the current guidelines of the Infectious Diseases Society of America recommend fluoroquinolones as firstline treatment for patients aged у65 years who have CAP [33] . In the Canadian tracking effort, the rate of levofloxacin resistance among the 2187 S. pneumoniae isolates obtained from this "older" population was found to have increased from 0 in Downloaded from https://academic.oup.com/cid/article-abstract/39/Supplement_3/S142/288433 by guest on 16 September 2019 1993 to 4.3% in 2001 [34] . Similarly, pneumococcal resistance to ciprofloxacin had increased from 0 to 7.2% over this same period, with the most rapid increases (for both agents) occurring between 1998 and 2001 [32] .
The limited but growing number of patients with infections due to fluoroquinolone-resistant S. pneumoniae may reflect the pluripotent ability of pneumococci to cause progressive disease in the face of fluoroquinolone therapy [35] . For example, a recent report describes 4 patients with pneumococcal pneumonia who had experienced failure of levofloxacin therapy [35] . In 1 patient, the fully fluoroquinolone-susceptible strain of S. pneumoniae became resistant to levofloxacin during therapy. In another patient without known prior fluoroquinolone exposure, infection was caused by a strain that harbored a first-step parC mutation conveying reduced levofloxacin susceptibility; this strain became fully resistant during therapy and was associated with levofloxacin treatment failure. The other 2 patients, who had been treated previously with ciprofloxacin, were infected by fluoroquinolone-resistant strains and had failure of levofloxacin therapy [35] . These data raise another warning signal with regard to the emergence and spread of fluoroquinolone antimicrobial resistance. In particular, patients who were previously exposed to fluoroquinolones could potentially harbor organisms with reduced susceptibility and, hence, could be at greater risk for developing infection with fluoroquinoloneresistant pneumococci. The authors suggested that recent exposure to a fluoroquinolone may contraindicate the use of another fluoroquinolone for treatment of pneumococcal respiratory infections [35] .
CONCLUSIONS
Data compiled by 3 major US and Canadian surveillance programs spanning much of North America and covering more than a decade show that antimicrobial resistance among bacterial respiratory tract pathogens is increasing. This may complicate an already significant clinical challenge in the treatment of CAP and other potentially serious RTIs. When considered in the light of reports of failure of therapy in patients infected by organisms with in vitro resistance, the trends in antimicrobial resistance, as shown in these surveillance programs, suggest that the selection of antimicrobial therapy for the treatment of RTIs is more complex today than ever before. Furthermore, changing antimicrobial resistance patterns may continue to narrow-instead of expand-pharmacotherapeutic options. Surveillance information will aid the clinician in appropriately targeting treatment in this increasingly difficult health care arena.
